Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

DT 168

Next Previous
X
Search
Drug Profile

DT 168

Alternative Names: DT-168

Latest Information Update: 08 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Design Therapeutics
  • Class Eye disorder therapies; Small molecules
  • Mechanism of Action Transcription factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Fuchs' endothelial dystrophy

Most Recent Events

  • 05 Aug 2024 Design Therapeutics plans a phase I trial (In volunteers) for Fuchs' endothelial dystrophy in 2024
  • 19 Mar 2024 US FDA approves IND application for DT 168 in Fuchs' endothelial dystrophy
  • 31 Dec 2023 Design Therapeutics has patent pending applications and two pending Patent Cooperation Treaty applications for "compositions of matter and methods for the treatment of Fuchs' endothelial dystrophy (FECD)" in the European Union and multiple countries worldwide

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top